RT @jitcancer: Breelyn Wilky (@breelynwilkyMD) from @CUCancerCenter presents Phase 1 data at #SITC22 from combo Botensilimab (modified aCTL…
3,396 followers
2,016 followers
RT @jitcancer: Breelyn Wilky (@breelynwilkyMD) from @CUCancerCenter presents Phase 1 data at #SITC22 from combo Botensilimab (modified aCTL…
8,160 followers
Breelyn Wilky (@breelynwilkyMD) from @CUCancerCenter presents Phase 1 data at #SITC22 from combo Botensilimab (modified aCTLA4) and balstilimab (aPD1) in patients with #IO refractory metastatic solid tumors. For more on #ICB, check out this #JITC review: h
31,693 followers
@DrCraigGedye @SanFranciscoGu1 @oncology_bg @barttels2 @NobelPrize @juliaoftoronto Here's the reference, I think: 'Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with me